

ARRAY BIOPHARMA INC  
Form 8-K  
December 14, 2009

---

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

**FORM 8K**

**CURRENT REPORT**

**Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 12, 2009**

**Array BioPharma Inc.**

(Exact name of registrant as specified in its charter)

**Delaware      000-31979      84-1460811**

(State or Other    (Commission    (IRS Employer  
Jurisdiction of  
Incorporation)    File Number)    Identification No.)

**3200 Walnut Street, Boulder, Colorado    80301**

(Address of Principal Executive Offices)    (Zip Code)

Registrant's telephone number, including area code:    **(303) 381-6600**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---

---

**Item 8.01. Other Events**

On December 12, 2009, Array BioPharma Inc. issued a press release announcing positive interim results for Phase 1 study of its HER2 inhibitor, ARRY-380, in cancer patients. The full text of this press release is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

99.1 Press release dated December 12, 2009 entitled "ARRAY BIOPHARMA ANNOUNCES POSITIVE INTERIM RESULTS FOR PHASE I STUDY OF ITS HER2 INHIBITOR, ARRY-380, IN CANCER PATIENTS."

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ARRAY BIOPHARMA INC.

Date: December 12, 2009 By: /s/ R. Michael Carruthers  
R. Michael Carruthers  
Chief Financial Officer

3

---

**EXHIBIT INDEX**

**Exhibit  
No.**

99.1 Press release dated December 12, 2009 entitled “ARRAY BIOPHARMA POSITIVE INTERIM RESULTS FOR PHASE 1 STUDY OF ITS HER2 INHIBITOR, ARRY-380, IN CANCER PATIENTS.”

4